Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160(MN) (ALVAC-HIV): A double-blind controlled randomized study of safety and immunogenicity

被引：0
|
作者：
Tubiana, R
Gomard, E
Fleury, H
Gougeon, ML
Mouthon, B
Picolet, H
Katlama, C
机构：
[1] HOP COCHIN,INSERM,U445,F-75674 PARIS,FRANCE
[2] VIROL LAB,BORDEAUX,FRANCE
[3] PASTEUR MERIEUX SERUMS & VACCINS,LYON,FRANCE
[4] INST PASTEUR,PARIS,FRANCE
来源：
AIDS | 1997年 / 11卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：819 / 820
页数：2
相关论文
共 50 条
  • [11] Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine
    Lambert, JS
    Viscidi, R
    Walker, MC
    Clayman, B
    Winget, M
    Wolff, M
    Schwartz, DH
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1997, 4 (03) : 302 - 308
  • [12] Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120 - A randomized, double-blind trial
    Graham, BS
    Keefer, MC
    McElrath, MJ
    Gorse, GJ
    Schwartz, DH
    Weinhold, K
    Matthews, TJ
    Esterlitz, JR
    Sinangil, F
    Fast, PE
    Wright, PF
    Dolin, R
    Corey, L
    Belshe, RB
    Clements, ML
    Bolognesi, DP
    Stablein, DM
    Chernoff, D
    Duliege, AM
    Walker, CM
    ANNALS OF INTERNAL MEDICINE, 1996, 125 (04) : 270 - +
  • [13] HUMAN-IMMUNODEFICIENCY-VIRUS (HIV-1) GP160-SPECIFIC LYMPHOCYTE PROLIFERATIVE RESPONSES OF MONONUCLEAR LEUKOCYTES FROM HIV-1 RECOMBINANT GP160 VACCINE RECIPIENTS
    KEEFER, MC
    BONNEZ, W
    ROBERTS, NJ
    DOLIN, R
    REICHMAN, RC
    JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (03): : 448 - 453
  • [14] A MULTICENTER RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED STUDY OF THE EFFECT OF RECOMBINANT GP160 VACCINE ON HIV DISEASE IN ASYMPTOMATIC INDIVIDUALS
    TSOUKAS, CM
    FONG, I
    GILL, J
    MONTANER, J
    RACHLIS, A
    SCHLECH, W
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 : S158 - S158
  • [15] A PRIME-BOOST APPROACH TO HIV PREVENTIVE VACCINE USING A RECOMBINANT CANARYPOX VIRUS EXPRESSING GLYCOPROTEIN-160 (MN) FOLLOWED BY A RECOMBINANT GLYCOPROTEIN-160 (MN/LAI)
    PIALOUX, G
    EXCLER, JL
    RIVIERE, Y
    GONZALEZCANALI, G
    FEUILLIE, V
    COULAUD, P
    GLUCKMAN, JC
    MATTHEWS, TJ
    MEIGNIER, B
    KIENY, MP
    GONNET, P
    DIAZ, I
    MERIC, C
    PAOLETTI, E
    TARTAGLIA, J
    SALOMON, H
    PLOTKIN, S
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (03) : 373 - 381
  • [16] Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection
    Salmon-Céron, D
    Excler, JL
    Finkielsztein, L
    Autran, B
    Gluckman, JC
    Sicard, D
    Matthews, TJ
    Meignier, B
    Valentin, C
    El Habib, R
    Blondeau, C
    Raux, M
    Moog, C
    Tartaglia, J
    Chong, P
    Klein, M
    Milcamps, B
    Heshmati, F
    Plotkin, S
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (07) : 633 - 645
  • [17] Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: Evaluation of the T cell proliferative response
    Ratto-Kim, S
    Sitz, KV
    Garner, RP
    Kim, JH
    Davis, C
    Aronson, N
    Ruiz, N
    Tencer, K
    Redfield, RR
    Birx, DL
    JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (02): : 337 - 344
  • [18] SAFETY AND IMMUNOGENICITY OF A GP120-DEPLETED, INACTIVATED HIV-1 IMMUNOGEN - RESULTS OF A DOUBLE-BLIND, ADJUVANT CONTROLLED TRIAL
    TRAUGER, RJ
    DAIGLE, AE
    GIERMAKOWSKA, W
    MOSS, RB
    JENSEN, F
    CARLO, DJ
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 : S74 - S82
  • [19] PRODUCTION OF LONG-LIVED NEUTRALIZING ANTIBODIES TO HIV-1 IIIB IN MICE WITH A VACCINIA RECOMBINANT VIRUS-INFECTED CELL VACCINE EXPRESSING GP160
    PARRY, C
    MCLAIN, L
    DIMMOCK, NJ
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (02) : 205 - 212
  • [20] Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers
    Birx, DL
    Loomis-Price, LD
    Aronson, N
    Brundage, J
    Davis, C
    Deyton, L
    Garner, R
    Gordin, F
    Henry, D
    Holloway, W
    Kerkering, T
    Luskin-Hawk, R
    McNeil, J
    Michael, N
    Pierce, PF
    Poretz, D
    Ratto-Kim, S
    Renzullo, P
    Ruiz, N
    Sitz, K
    Smith, G
    Tacket, C
    Thompson, M
    Tramont, E
    Yangco, B
    Yarrish, R
    Redfield, RR
    JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03): : 881 - 889
12345